Citations

Clear

1828 citation(s) found for "Su, Emily".

Distinct Tau PET Dynamics in Early vs. Late Age-of-Onset Alzheimer’s disease
Chiotis, Konstantinos, Soleimani-Meigooni, David N, Aisen, Paul S, Amuiri, Alinda, Atri, Alireza, Beckett, Laurel, Brickhouse, Michael , Clark, David G, Dage, Jeffrey L, Day, Gregory S, Duara, Ranjan, Eloyan, Ani , Foroud, Tatiana, Graff-Radford, Neill R, Grant, Ian M, Hammers, Dustin B, Honig, Lawrence S, Johnson, Erik C. B., Jones, D. Richard, Kirby, Kala, Koeppe, Robert, Kramer, Joel H, Kukull, Walter A, Leuzy, Antoine , Masdeu, Joseph C., Mendez, Mario F., Musiek, Erik, Nudelman, Kelly N., Onyike, Chiadi U., Riddle, Meghan, Rocha, Salma, Rogalski, Emily, Salloway, Stephen, Schonhaut, Daniel R., Sha, Sharon, Shankar, Ranjani, Taurone, Alexander, Thangarajah, Maryanne, Toga, Arthur W., Touroutoglou, Alexandra, Turner, Raymond Scott, Vemuri, Prashanthi, Wingo, Thomas S., Wolk, David A., Womack, Kyle, Zhang, J. , Carrillo, Maria C., Dickerson, Bradford C., Apostolova, Liana G., Joie, Renaud La, Rabinovici, Gil D., Chiotis, Konstantinos , Blazhenets, Ganna , Soleimani‐Meigooni, David N. , Aisen, Paul , Atri, Alireza , Beckett, Laurel , Clark, David G., Dage, Jeffrey L. , Day, Gregory S. , Duara, Ranjan , Foroud, Tatiana , Graff‐Radford, Neill R. , Hammers, Dustin B , Honig, Lawrence S. , Johnson, Erik C. B. , Jones, David T. , Koeppe, Robert A. , Kramer, Joel H. , Kukull, Walter A. , Lagarde, Julien , Maiti, Piyush , Masdeu, Joseph C , Mendez, Mario F. , Musiek, Erik , Nudelman, Kelly , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen, Schonhaut, Daniel R. , Sha, Sharon J. , Shankar, Ranjani , Taurone, Alexander, Thangarajah, Maryanne, Toga, Arthur W. , Touroutoglou, Alexandra , Turner, Raymond Scott , Vemuri, Prashanthi , Wingo, Thomas S , Wolk, David A. , Womack, Kyle , Carrillo, María C. , Dickerson, Bradford Clark , Apostolova, Liana G. , Joie, Renaud La , Rabinovici, Gil D.

Mayo Clinic

No container title available | January 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.25.26344738 | PMID 41646765 Get It

Abstract Early-onset Alzheimer’s disease (EOAD) and Late-onset AD (LOAD) differ in clinical presentations and rates of progression. We aimed to compare baseline and longitudinal tau PET burden, and their relationship with clinical variables in amyloid-PET positive, cognitively impaired participants from the Longitudinal Early-Onset Alzheimer’s Disease Study (EOAD; n=390) and Alzheimer’s Disease Neuroimaging Initiative (LOAD; n=211). Patients with EOAD showed higher baseline tau PET retention, broader neuroanatomical involvement and faster accumulation rates over time compared to LOAD, after adjusting for amyloid load and clinical stage. Tau PET showed stronger correlations with baseline amyloid burden and clinical measures of global cognition and function in EOAD than LOAD. We conclude that earlier age of onset in AD is linked to a more aggressive tauopathy, which in turn is a primary driver of clinical decline. These findings suggest that optimal therapeutic targets and strategies may differ between EOAD and LOAD. One Sentence Summary Younger patients with Alzheimer’s disease show more aggressive tau spread, suggesting age of onset defines distinct disease pathways with key clinical implications.
International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR
Alger, Emily , Aiyegbusi, Olalekan Lee , Dueck, A. C. , Minchom, Anna, pe, madeline, Peipert, John Devin , Snyder, C. J., Symeonides, Stefan N. , Wilson, Roger , Basch, Ethan , Qiao, Yu , Dean, Lizzie, Hansen, Aaron R. , Kholmanskikh, Olga , Kobayashi, Ken, Tourneau, Christophe Le, Lee, J. Jack, Patel, Sheetal, Petrie, Joan, Pond, Gregory R. , Prior, Kieran, Rantell, Khadija , Reeve, John F., Solovyeva, O., Wages, Nolan A. , Weber, Harald A., Yap, C., Dueck, Amylou C. , Yap, Christina , Snyder, Claire , Minchom, Anna , Snyder, Claire , Bates, Susan E , Bulbeck, Helen , Di Maio, Massimo , Hansen, Aaron R , Kholmanskikh, Olga , Kobayashi, Ken , Landers, Dónal , Lee, J Jack , Ma, Brigette B Y , Marshall, Lynley V , Petrie, Joan , Pond, Gregory Russell , Solovyeva, Olga , Wages, Nolan A , Yap, Christina , Peipert, John Devin , Pe, Madeline , Basch, Ethan , Bates, Susan E. , Bulbeck, Helen , Tourneau, Christophe Le , Ma, Brigette , Weber, Harald, Calvert, Melanie

Mayo Clinic

Journal of Clinical Oncology | January 23, 2026 | Volume: 44 | Issue: 8 | Pages: 709-719

10.1200/jco-25-01625 | PMID 41576310 Get It

PURPOSE There is growing scientific interest in incorporating patient-reported outcomes (PROs) in early phase dose-finding oncology trials (DFOTs) to assess tolerability, inform dose selection, and guide later stage trial design. However, research indicates that PRO objectives in DFOTs are often unclear. The Incorporating Patient-Reported Outcomes in Dose-Finding Trials-Research Objectives Recommendations (OPTIMISE-ROR) project was established to support trialists to effectively incorporate PROs into DFOTs. METHODS Using the Enhancing Quality and Transparency of Health Research (EQUATOR) Network's methodological framework, guideline development included the following: (1) a methodological review of published DFOTs incorporating PROs; (2) candidate item generation, refined through expert consultation; (3) a two-round international multistakeholder Delphi survey (N = 109 in Round 1 [October 2024]; N = 96 in Round 2 [December 2024]); and (4) an independently chaired virtual consensus meeting (N = 31; January 2025) where multidisciplinary, international experts reviewed and voted to finalize items for inclusion. RESULTS Consensus was reached on six recommendations emphasizing three core PRO tolerability concepts: overall side effect impact, symptomatic adverse events, and overall health-related quality of life. The integration of PROs to inform final dose recommendations in dose escalation and optimization trials should be considered, regardless of trial design. The recommendations highlight the importance of PRO data analysis over time and across dose levels, defining PRO research objectives as descriptive or statistically powered, and assessing PRO-related end points to guide end point selection for subsequent studies. CONCLUSION This foundational guidance outlines key PRO research objectives in DFOTs. By facilitating the systematic integration of PROs, this guidance supports the utilization of patient-centered evidence for the tolerability and efficacy assessment of therapies to inform dose escalation, optimization, and regulatory evaluation—ultimately contributing to the development of safer, more effective therapies.
Neuroinflammation demonstrated by 11 C‐ER176 PET with amyloid and tau pathology
Kandimalla, Mahathi , Lim, Seokbeen , Jacobson, David N, Lee, Jeyeon, Min, Paul H., Nycklemoe, Marin, Lee, Seung Baek, Botha, Hugo, Graff‐Radford, Jonathan, Jones, D. Richard, Vemuri, Prashanthi, Kantarci, Kejal, Knopman, David S., Jack, Clifford R., Petersen, Ronald C., Lowe, VJ, Min, Hoon‐Ki , Lee, Seung Baek , Lim, Seokbeen , Nycklemoe, Marin E, Lundt, Emily S. , Lowe, Val J , Min, Hoon-Ki Paul , Lee, Seung Baek , Lee, Jeyeon, Botha, Hugo , Graff‐Radford, Jonathan , Jones, David T. , Cogswell, Petrice M. , Vemuri, Prashanthi , Kantarci, Kejal , Knopman, David S. , Jack, Clifford R. , Petersen, Ronald C.

Mayo Clinic

Alzheimer's & Dementia | January 23, 2026 | Volume: 22 | Issue: 1 | Pages: No page available

10.1002/alz.71027 | PMID 41574776 Get It

Abstract INTRODUCTION Understanding neuroinflammation across the Alzheimer's disease (AD) spectrum is essential to elucidate disease mechanisms and individualize therapy. METHODS Human microglial translocator protein (TSPO) expression under inflammatory stimuli was assessed by immunoblot experiments. Ninety‐six participants were enrolled across four groups: cognitively unimpaired amyloid (CU A) + and −, mild cognitive impaired (MCI) A+, and Alzheimer's disease dementia (ADD) A+. Neuroinflammation using 11 C‐ER176 TSPO positron emission tomography (PET) was compared to amyloid and tau PET. Correlations between neuroinflammation, amyloid, and tau pathology were examined across disease stages. RESULTS TSPO was upregulated in human microglia under AD‐like inflammatory conditions. Neuroinflammation, defined by PET TSPO, increased in CU A+ participants and became more widespread with increasing disease severity, aligning with worsening amyloid and tau pathology. Associations with tau were particularly extensive in temporal and parietal regions. DISCUSSION These findings suggest probable amyloid association with early microglial activation, while tau pathology is closely tied to wider distribution of neuroinflammation. Highlights TSPO expression increases in human microglia under AD‐like inflammation. 11 C‐ER176 PET shows stage‐dependent neuroinflammation across the AD spectrum. Neuroinflammation overlaps with tau and is more widespread in amyloid‐positive individuals. Activity peaks in MCI, stabilizes later, and relates to vascular and neurodegenerative changes.
AI-generated data contamination erodes pathological variability and diagnostic reliability
He, Hongyu , Xiang, Shaowen, Zhang, Y. P. , Zhu, Yingtao, Zhang, Jin, Lu, Yunyi, Deng, Hao, Alsentzer, Emily, Chen, Qingyu, Yu, Kun‐Hsing , Marshall, Andrew, Chen, Tingting, Anumasa, Srinivas, Ebner, Daniel, Ho, Dean, Cheng, Ching-Yu, Liu, Dianbo, Deng, Hao , Alsentzer, Emily , Liu, Yun , Chen, Qingyu , Yu, Kun‐Hsing , Chen, Tingting, Anumasa, Srinivas, Ebner, Daniel, Ho, Dean , Ngiam, Kee Yuan , Cheng, Ching-Yu

Mayo Clinic

No container title available | January 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.19.26344383 Get It

Abstract Generative artificial intelligence (AI) is rapidly populating medical records with synthetic or partially AI-generated content, creating a feedback loop where future models are increasingly at risk of training on uncurated AI-generated data. However, the clinical consequences of this AI-generated data contamination remain unexplored. Here, we show that in the absence of mandatory human verification, this self-referential cycle drives a rapid erosion of pathological variability and diagnostic reliability of medical data at population scale. By analysing more than 800,000 synthetic data points across clinical text generation, vision–language reporting, and medical image synthesis, we find that models progressively converge toward generic phenotypes regardless of the model architectures. Specifically, rare but critical findings, including pneumothorax and effusions, vanish from the synthetic content generated by AI models, while demographic representations skew heavily toward middle-aged male phenotypes. Crucially, this degradation is masked by false diagnostic confidence. Models continue to issue reassuring reports while failing to detect life-threatening pathology, with false reassurance rates tripling to 40%. Blinded physician evaluation confirms that this decoupling of confidence and accuracy renders AI-generated documentation clinically useless after just two generations. We systematically evaluate three mitigation strategies that can be easily integrated into existing clinical workflows, finding that while synthetic volume scaling fails to prevent collapse, mixing real data with quality-aware filtering effectively preserves diversity. Ultimately, our results suggest that without policy-mandated human oversight, the deployment of generative AI threatens to degrade the very healthcare data ecosystems it relies upon.
Regulatory T-cell Sensing of Extracellular ATP via P2RX7 Promotes Their Accumulation and Suppression and Drives Lung Tumor Growth
Santiago-Carvalho, Igor , Francisco, Ronaldo da Silva , Macedo, Bruna de Gois , Salgado, Caio Loureiro , Stoll, Carly R. , Shao, Samantha C. , Beniwal, Angad , Kwok, Tina , Banuelos, Alma , Cione, Marcos Pinheiro , White, Emily , Johnston, Tyler, Leff, Chloe , Silva-Junior, Ildefonso , Souza, Fabio Carvalho de, Thant, Win , Fernandez-Bussy, Sebastian, Abia-Trujillo, David, Vu, Linh H, Husta, Bryan C, Copland, John A. , Gounari, Fotini , Justilien, Verline , Cione, Marcos Vinícios Pinheiro , Francisco, Ronaldo , Macedo, Bruna Gois , Johnston, Tyler M , Leff, Chloe Liliana , Carvalho de Souza, Fabio , Pandya, Prita , D'Império Lima, Maria Regina , Fernandez-Bussy, Sebastian , Abia-Trujillo, David , Vu, Linh H , Tran, Nhan L , Husta, Bryan C , Copland, John A , Gounari, Fotini , Justilien, Verline , Lancaster, Jessica N , Borges da Silva, Henrique , Silva, Ildefonso , Pandya, Prita , Lima, Maria Regina D’Império , Tran, Nhan L. , Lancaster, Jessica N. , Silva, Henrique Borges da

Mayo Clinic

Cancer Immunology Research | January 21, 2026 | Volume: 14 | Issue: 4 | Pages: 658-675

10.1158/2326-6066.cir-25-0567 | PMID 41564348 Get It

Abstract Lung cancer is the leading cause of cancer-related deaths worldwide, and despite advances in treatment, immune suppression remains an obstacle to effective therapy. Effector CD4+ T cells (CD4+ Teff) are critical for antitumor immunity, but their function is often inhibited by regulatory T cells (Treg), which accumulate in lung tumors and mediate suppressive functions through multiple mechanisms. This suppression leads to tumor progression and poor patient outcomes. However, the mechanisms underlying Treg-mediated suppression are not fully understood. Herein, we identify the extracellular adenosine 5-triphosphate receptor P2RX7 as a key regulator of Treg function in lung tumors. In a murine lung cancer model induced by Lewis lung carcinoma cells, we found that P2RX7 enhanced the suppressive capacity of tumor-infiltrating Tregs, promoting tumor growth. In T cell–specific P2RX7-knockout (P2RX7-KO) mice, reduced Treg infiltration was accompanied by increased CD4+ Teff accumulation and improved tumor control. Treg-specific P2RX7-KO mice exhibited reduced tumor growth, confirming a Treg-intrinsic role of P2RX7. Suppression assays revealed that tumor-infiltrating wild-type Tregs had greater suppressive activity compared with P2RX7-KO Tregs, which failed to inhibit type 1 and follicular helper T–like responses. This was associated with increased tumor-specific IgG production by lung B cells in P2RX7-KO mice. We also observed that wild-type Tregs expressed higher levels of the immunosuppressive molecule CTLA-4 when compared with P2RX7-KO Tregs. Thus, we conclude that P2RX7 expression on Tregs is essential for their suppressive function in lung cancer and targeting P2RX7 may constitute a strategy to improve lung cancer treatment by alleviating Treg-mediated immune suppression.
P0762 Defining Quality Pouch Surgery – A Critical Step Towards Centralization? International Consensus on Key Performance Indicators in Pouch Surgery (KPIPS) Study
Holubar, S, Soop, M., Poskus, T, Neary, P, Uchino, Tairin , Yang, S S, Adamina, M, Avellaneda, N L, Barnes, E, Brouquet, A, Brown, S R, Overstraeten, A De Buck Van, Buskens, C J, Chiorean, Michael , Clark, D, Cohen, B, Ouali, S El, Faiz, O D, Hahnloser, Dieter, Hancock, L, Herfarth, H, Johnston, M, Kayal, M, Laharie, D, Liberman, S, Loftus, E, Moeslein, G, Myrelid, P, Qazi, Taha , Raffals, L, Rubin, D T, Spinelli, A, Steinhagen, Emily , Verstock, Bram, Warusavitarne, J, Wexner, S, Winter, D, Group, KPIPS Study, Verstockt, Bram , Clark, David A. , Verstockt, B , Holubar, Stefan D. , Poškus, Tomas , Neary, Peter, Brouquet, Antoine , Overstraeten, Anthony de Buck van , Buskens, Christianne Johanna , Ouali, Sara El , Faiz, Omar , Fichera, Alessandro , Hahnloser, Dieter , Herfarth, Hans , Kayal, Maia , Laharie, David , Liberman, Sender A., Myrelid, Pär , Poylin, Vitaliy Y. , Raffals, Laura E. , Spinelli, A, Tozer, Phil J. , Wexner, Steven D

Mayo Clinic

Journal of Crohn’s and Colitis | January 21, 2026 | Volume: 20 | Issue: Supplement_1 | Pages: No page available

10.1093/ecco-jcc/jjaf231.943 Get It

Abstract Background Global data demonstrate an inverse relationship between hospital ileoanal pouch volume and adverse outcomes, highlighting the need for quality metrics for this technically demanding procedure.1-4 Currently, there are no standardised quality indicators to define high-quality pouch surgery. This study aimed to establish international consensus on key performance indicators (KPIs) in pouch surgery. Methods A modified Delphi process was conducted among an international, multidisciplinary panel of experts. Participants were identified through professional networks, literature review, and direct email invitation; additional participants recruited via a snowball sampling approach over one month. Candidate KPIs were generated from literature review and expert input across 5 domains. Each item was rated on a 9-point Likert scale (1 = not important, 9 = critically important); consensus was predefined as ≥ 80% of respondents rating an item 7–9. Items not reaching consensus were re-rated in a second round following anonymized group feedback. Results Round 1 included 312 participants from 37 countries. Demographics (Table 1): 53% were age 45 years, 35.2% were female, and included surgeons (68.6%) and gastroenterologists (31.1%). Most (76.6%) practice at academic or university hospitals, with a median of 11 (5–17) years in practise; 78.9% perform >1 pouchoscopy per month, and 39.5% of surgeons perform 5 pouches/year. Respondents’ regions included North America (51%), Europe (26%), Oceania (9%), Asia (6%), Latin America (4%), and the Middle East/Africa (4%). Seven (18%) countries (Denmark, Lithuania, Malaysia, Norway, United Arab Emirates, Sweden, and Switzerland) reported pouch surgery is already centralised, while 70.6% agreed pouch centralisation should be implemented. Cost/logistics and professional autonomy were the most important barriers to centralisation, whereas capacity and training exposure were least important. Overall, 37/59 (62.7%) candidate KPIs reached consensus after Round 1. The Round 2 response rate was 61%, and 2 additional KPIs reached consensus (preop ileitis and long-term risk of pouchitis). Additionally, 14 of 25 (56%) informed consent items reached consensus, and 64% of respondents felt informed consent for pouch surgery requires 2 or more office visits. Consensus items were used to populate a KPIPS Checklist (Figure 1). Conclusion Through an international Delphi process, the KPIPS study identified a consensus-derived set of key performance indicators to measure quality in pouch surgery. These quality metrics provide a foundation for benchmarking outcomes and represent a critical step towards centralization and the development of designated pouch centres of excellence to improve global standards of care for pouch patients. References: 1. Worley GHT, Fearnhead NS, Brown SR, et al. Review of current practice and outcomes following ileoanal pouch surgery: Lessons learned from the ileoanal pouch registry and the 2017 ileoanal pouch report. Colorectal Dis 2018;20:913–22. 2. Giddings HL, Yang PF, Steffens D, Solomon MJ, Ng KS. Influence of hospital-level and surgeon factors on the outcomes after ileo-anal pouch surgery for inflammatory bowel disease: Systematic review. Br J Surg 2024;111. 3. Hoang CM, Maykel JA, Davids JS, et al. Distribution of elective ileal pouch-anal anastomosis cases for ulcerative colitis: A study utilizing the university health system consortium database. J Gastrointest Surg 2020;24:2613–9. 4. Moojen TB, Visser E, Reijntjes MA, et al. One-year stoma-free survival of ileoanal pouches for uc in european centers: The miracle project. Ann Surg Open 2025;6:e596. Conflict of interest: Prof. Holubar, Stefan: No conflict of interest Soop, Mattias: No conflict of interest Poskus, Tomas: No conflict of interest Neary, Peter: No conflict of interest Uchino, Tairin: No conflict of interest Yang, Song-soo: No conflict of interest Adamina, Michel: No conflict of interest Avellaneda, Nicolas Luis: No conflict of interest Barnes, Edward: No conflict of interest Brouquet, Antoine: No conflict of interest Brown, Steven Ross: No conflict of interest De Buck Van Overstraeten, Anthony: No conflict of interest Buskens, Christianne J.: No conflict of interest Chiorean, Michael: No conflict of interest Clark, David: No conflict of interest Cohen, Benjamin: No conflict of interest El Ouali, Sara: No conflict of interest Faiz, Omar Darius: No conflict of interest Fichera, Alessandro: No conflict of interest Hahnloser, Dieter: No conflict of interest Hancock, Laura: No conflict of interest Herfarth, Hans: No conflict of interest Johnston, Michael: No conflict of interest Kayal, Maia: No conflict of interest Laharie, David: No conflict of interest Liberman, Sender: No conflict of interest Loftus, Jr, Edward: No conflict of interest Moeslein, Gabriela: No conflict of interest Myrelid, Pär: No conflict of interest Poylin, Vitaliy: No conflict of interest Qazi, Taha: No conflict of interest Raffals, Laura: No conflict of interest Rubin, David T.: No conflict of interest Spinelli, Antonino: No conflict of interest Steinhagen, Emily: No conflict of interest Tozer, Philip: No conflict of interest Verstockt, Bram: No conflict of interest Warusavitarne, Janindra: No conflict of interest Wexner, Steven: No conflict of interest Winter, Desmond: No conflict of interest
A randomized, double-blind, placebo-controlled trial of soluble corn fiber supplementation for children with asthma
Rank, Matthew A. , Barroso, Daisy L., Conn, Kathryn A, Pecak, Melissa, Scandura, Matthew, Hirsch, Allyson H., Gu, Haiwei, Shearer, Heather L. , Johnson, Darcy, Argel, Natalia, Bauer, Cindy S., Williams, S.N., Woodward, James, Cope, Emily K. , Wright, Benjamin L. , Wright, Benjamin L , Gu, Haiwei , Whisner, Corrie Marie , Shearer, Heather, Woodward, James

Mayo Clinic

Frontiers in Allergy | January 21, 2026 | Volume: 6 | Issue: No issue available | Pages: No page available

10.3389/falgy.2025.1707834 | PMID 41647190 Get It

Introduction Asthma is a multifactorial disease influenced by genetic and environmental factors, including diet. The gut microbiome contributes to airway inflammation via the gut-lung axis, partly through production of short chain fatty acids (SCFAs) from bacterial fermentation of dietary fiber. We hypothesized that dietary fiber supplementation could modulate the gut microbiome and increase SCFAs in children with asthma. Methods This is a double-blind, placebo-controlled trial of children who were randomized to consume 12 g of soluble corn fiber (SCF) as a supplement to their usual daily diet (50% the recommended daily fiber intake) or placebo for 4–6 weeks ( clinicaltrials.gov NCT03673618). Dietary surveys, asthma symptom questionnaires, fecal, blood and nasal samples were collected before and after the intervention period to quantify fiber intake, asthma control, nasal and gut microbiome, and serum short chain fatty acids (SCFAs). Results Of the 20 children enrolled, 15 completed the intervention with an average adherence rate of 83%. SCFA concentrations and gut microbiome changes varied by individual and treatment group. No significant differences in gut or nasal alpha or beta diversity were observed between groups post-intervention. However, differential abundance analysis showed a trend toward increased Bifidobacterium in the SCF group compared to placebo (ANCOM-BC p = 0.0004, FDR q = 0.073). Discussion Supplementation of 50% of recommended daily fiber intake had minimal impact on asthma symptoms, the microbiome, or SCFA levels. Future studies should consider higher fiber doses, different fiber types, or targeting individuals with low baseline fiber intake to account for observed variability in microbiome and SCFA responses. Clinical Trial Registration https://clinicaltrials.gov/study/NCT03673618 , identifier NCT03673618.
Clinical Characteristics and Outcomes of Pneumocystis Pneumonia in Solid Organ Transplant Recipients
Pulsipher, Aaron M. , Thompson, Emily, Vikram, Holenarasipur R. , Cartin‐Ceba, Rodrigo , Wengenack, Nancy L. , Sen, Ayan, Lee, Augustine S. , Ham, Kealy R., Thompson, Emily , Vikram, Holenarasipur R. , Thompson, Emily R , Pulsipher, Aaron M , Gotway, Michael B. , Limper, Andrew H.

Mayo Clinic

Transplant Infectious Disease | January 19, 2026 | Volume: 28 | Issue: 2 | Pages: No page available

10.1111/tid.70171 | PMID 41553911 Get It

ABSTRACT Background Solid organ transplant (SOT) recipients are at risk for Pneumocystis jirovecii pneumonia (PCP), yet how their clinical phenotype and outcomes compare with other immunocompromised patients without HIV remains poorly defined. Methods We conducted a multicenter retrospective cohort study of adults with proven or probable PCP from 2017 to 2025, including 95 SOT recipients and 588 non‐SOT, non‐HIV immunocompromised patients. The primary outcome was 90‐day mortality, secondary outcomes included new renal failure requiring dialysis, and 30‐day mortality. Outcomes were analyzed using inverse probability weighting (IPW) with winsorization to adjust for baseline differences. Results In unadjusted analysis, SOT recipients had lower 90‐day mortality (hazard ratio [HR]: 0.62, 95% CI 0.39–0.97, p = 0.037). After IPW with winsorization of extreme weights, SOT status remained associated with lower 90‐day mortality (HR: 0.32, 95% CI 0.13–0.76, p = 0.009), and 30‐day mortality (HR: 0.35, 95% CI: 0.14–0.92, p = 0.034). SOT recipients had higher odds of renal failure requiring dialysis in unadjusted analysis (OR: 3.49, 95% CI 1.94–6.14, p < 0.001), which persisted after IPW adjustment (OR: 1.62, 95% CI: 1.04–2.51, p = 0.032). Conclusions Despite higher rates of renal failure requiring dialysis, SOT recipients with PCP experienced significantly improved short‐ and intermediate‐term survival compared with other non‐HIV immunocompromised patients, underscoring the need for further investigation into transplant‐associated contributors to PCP outcomes.
Establishing Reference Values in Healthy Participants for the Cardiac Troponin T High-Sensitivity Gen 6 Assay: REF-TSIX Global Reference Study
Daniels, Lori B. , Mueller, Christian, Giannitsis, Evangelos, Meex, Steven J. R., Buehlmann, David, Dilba, Peter, Bendig, Garnet, Cole, Mette, Body, Richard, Christenson, Robert H, deFilippi, Christopher R, Inoue, Kenji, Jaffe, A S, McCarthy, Cian P. , McCord, J., Neumann, Johannes T, Omland, T., Papendick, Cynthia , Sandoval, Yader, Twerenbold, Raphael, Peacock, W Frank, Mills, Nicholas L, investigators, the TSIX, Jacobs, Michael B., Lucksinger, Gregg, Powell, Richard, Johnson, Daniel, Coleman, Hugh, Fein, M, Surber, Joseph, Vu, Jack B., Hassman, Michael, Hernandez, John, Kirstein, Judith, Tomaszewski, Christian, Runyon, Michael S. , Gong, Jonathan , Wein, D., Andrabi, Sara , Kopin, David , Larrain, Germain, Tahirkheli, Naheem, Clemency, Brian, Abdullah, Shuaib, Hira, Ravi S. , Klausner, H A, Mahler, Simon A. , Crystal, Chad, Headden, Gary, Chaille, Peter, Cannon, Chad Aaron, Limkakeng, Alexander, Tolia, Vaishal , Knapp, Barry J., Massoomi, Mohammad, Sandoval, Yader, Ko, Emily, Luzzi, Verónica, Christenson, Robert, Carson, Jennifer Powers , Cacioppo, F , Kolev, E., Petrov, Andrey, Hazarbasanov, Dobri , Simova, lana, Magimaiseelan, Luci Suganthi, Kosch, Christine, Klein, G, Mehltretter, Kai, Sauter, Joachim, Baumann, Sybille, Moeckel, Martin, Twerenbold, Raphael, Muller-Hennessen, Matthias, Biener, Moritz , Findeisen, P., Omland, Torbjøm, Wilczek-Kosowska, Urszula, Zimmer-Satora, Ewa, Krecipro-Nizińska, Ewa, Miró, O, Díaz, Víctor Jiménez , Mueller, C, Christ, Michael, Lynch, Stephen, BODY, R. A. F., Matsuki, Shunji, Eto, Takashi, Tanaka, Takanori, Hanada, Ryuzo, Nakagami, Takuo, Nakama, T, Kadota, K., Jing, Shan, Yu, Shuwen, Zhang, Hongxuan, Zhang, Jun, Huo, Yong, Zhang, Yan, Yan, Li, Jiang, Longyuan, Chen, Weiqiang, Huang, Jianying, Zhao, Yan, Guan, Ling, Yang, Yanhua, Zhang, Qin, Qiu, Zhaohui, Body, Richard , Neumann, Franz–Josef , Müller, Christian , Mueller, Christian , Body, Rick , Eggers, Kai M. , Jaffe, Allan S. , Neumann, Johannes T , Sandoval, Yader , Tan, Jack Wei Chieh , Than, Martin , Twerenbold, Raphael , Mills, Nicholas L , Daniels, Lori B , Giannitsis, Evangelos , Meex, Steven J.R. , Christenson, Robert H. , Cobbaert, Christa M. , deFilippi, Christopher R. , McCord, James , Omland, Torbjørn , Sandoval, Yader , Tan, Jack Wei Chieh , Than, Martin , Twerenbold, Raphael , Surber, Joseph, Tomaszewski, Christian, Clemency, Brian, Headden, Gary , Cannon, Chad, Knapp, Barry , Tran, Nam K , Niederdöckl, Jan Daniel , Kolev, Emil, Popov, Todor, Sauter, Joachim, Baumann, Sybille , Möeckel, Martin , Müller‐Hennessen, Matthias, Findeisen, Peter, Scharnhorst, Volkher , Omland, T, Krecipro-Nizińska, Ewa, Christ, Michael , Nakagami, Takuo, Huo, Yong

Mayo Clinic

Clinical Chemistry | January 18, 2026 | Volume: 72 | Issue: 4 | Pages: 488-502

10.1093/clinchem/hvag011 | PMID 41564003 Get It

Abstract Background Measurement of cardiac troponin (cTn) using high-sensitivity assays is recommended for the diagnosis of myocardial infarction. We determined sex-specific and uniform 99th percentile upper reference limits (URLs) using the new Elecsys® Troponin T high-sensitivity Gen 6 assay in a global, healthy reference range cohort. Methods Lithium-heparin plasma and serum samples were prospectively collected from apparently healthy individuals aged ≥20 years across 34 global sites in the United States, Europe, China, and Japan. cTnT was measured using the Troponin T high-sensitivity Gen 6 assay on the Cobas® e 801 analyzer. Exclusion criteria were defined according to the 2022 IFCC guidance. Uniform and sex-specific 99th percentile URLs and nonparametric 95% CIs were determined in plasma and serum separately and combined. Results The final study population comprised 4147 participants (52.5% female) with a median (25th–75th percentiles) age of 48.0 (33.0–59.0) years; 45.8%, 47.9%, 5.2%, and 1.1% were White, Asian, Black, and other/unknown, respectively. For sample matrices combined (n = 8294), 81.0% and 99.2% of cTnT values were above the limit of detection in females and males, respectively. Sex-specific 99th percentile URLs (95% CI) were 18 (16–23) ng/L for females and 32 (28–35) ng/L for males; the uniform 99th percentile URL was 27 (24–31) ng/L. URLs were comparable in plasma and serum samples. Conclusions This study determined sex-specific and uniform 99th percentile URLs for the Troponin T high-sensitivity Gen 6 assay that were comparable irrespective of the matrix used in a large, global, healthy reference population.